Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Imviva Biotech
Imviva Biotech Presents Data Demonstrating Durable Clinical Responses from Ongoing Phase 1/2 Study of CTA313 in Systemic Lupus Erythematosus at ASGCT 2026
May 14, 2026
From
Imviva Biotech
Via
GlobeNewswire
Imviva Biotech to Present Clinical Data from Ongoing Phase 1/2 Study of CTA313 at the American Society of Gene & Cell Therapy's Annual Meeting
April 29, 2026
From
Imviva Biotech
Via
GlobeNewswire
Imviva Biotech Announces Acceptance of Late-Breaking Abstract Highlighting Data from Ongoing Phase 1/2 Study of CTA313 at 15th European Lupus Meeting
March 02, 2026
From
Imviva Biotech
Via
GlobeNewswire
Imviva Biotech Receives FDA Orphan Drug Designation for CTD402 for the Treatment of T-Cell Leukemia and Lymphoma
January 27, 2026
From
Imviva Biotech
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.